Patent 7842681 was granted and assigned to Abbott on November, 2010 by the United States Patent and Trademark Office.
Methods of reducing the number of platelets in mammals and preventing or treating pro-thrombotic conditions and diseases that are characterized by an excess of, or undesired activation of, platelets using inhibitors of anti-apoptotic Bcl-2 family protein members is disclosed.